Search

Search Results
Results 4711 - 4720 of 4758 for multiple sclerosis
  • Exploring cytokine networks in autoimmune diseases and advances in therapy
    White Paper - 19 Jun 2025
    This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.
  • Lioresal Tablets
    Drug - 12 Jun 2025
    Consumer Medicine Information (CMI) about Lioresal Tablets intended for persons living in Australia.
  • Enbrel
    Drug - 6 Jun 2025
    Consumer Medicine Information (CMI) about Enbrel intended for persons living in Australia.
  • Amgevita
    Drug - 13 May 2025
    Consumer Medicine Information (CMI) about Amgevita intended for persons living in Australia.
  • Inflectra
    Drug - 7 Apr 2025
    Consumer Medicine Information (CMI) about Inflectra intended for persons living in Australia.
  • Humira
    Drug - 11 Mar 2025
    Consumer Medicine Information (CMI) about Humira intended for persons living in Australia.
  • Top Sessions: 15th Clinical Biomarkers & CDx Summit Europe
    White Paper - 6 Mar 2025
    Discover the top sessions at Hanson Wade's 15th Clinical Biomarkers & CDx Summit Europe.
  • Top challenges: 15th Clinical Biomarkers & CDx Summit Europe
    White Paper - 6 Mar 2025
    Discover the top challenges tackled at Hanson Wade's 15th Clinical Biomarkers & CDx Summit Europe
  • Expanding new trends and technologies in ADC therapeutics
    White Paper - 18 Feb 2025
    Explore the latest advancements and innovative technologies in ADC therapeutics, driving new possibilities for targeted drug delivery.
  • Diaformin (AF)
    Drug - 17 Dec 2024
    Consumer Medicine Information (CMI) about Diaformin (AF) intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback